Press Releases October 5, 2026 08:30 AM

Aprea Therapeutics to Present at October Conferences

Aprea Therapeutics Announces CEO Participation at October 2026 Growth and Biotechnology Conferences

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
APRE

Aprea Therapeutics, a clinical-stage oncology company developing targeted therapies for biomarker-defined cancers, announced that CEO Oren Gilad will participate in the 2026 Maxim Growth Summit and Regional Biotechnology Conference. The company emphasizes its precision medicine approach aiming to exploit cancer cell vulnerabilities while minimizing toxicity, with lead programs APR-1051 and ATRN-119 in clinical development.

Aprea Therapeutics to Present at October Conferences
APRE
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Aprea Therapeutics will feature at two significant October 2026 industry conferences, increasing visibility among investors and partners.
  • The company's precision oncology approach targets cancer cell mutations to minimize toxicity, addressing ovarian, colorectal, prostate, and breast cancers.
  • Lead clinical programs include APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both targeting solid tumors.

DOYLESTOWN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad PhD, President and CEO, will participate in the 2026 Maxim Growth Summit, to take place October 12-14 in New York City and the Regional Biotechnology Conference, to take place October 15 in Doylestown, PA.

Maxim Growth Summit

Date and Time:Wednesday, October 14, 9am ETFormat:Fireside ChatLocation:Hard Rock Hotel, New York City  

A webcast of the fireside chat will be available on demand to registered conference attendees. For more information and a complete agenda, please refer to https://www.maximgrp.com/2026-growth-summit.

If you would like to arrange a 1on1 meeting with Aprea management during the conference, please contact your Maxim representative.

Regional Biotechnology Conference 2026

Date and Time:Thursday, October 15, 9am – 12noon ETFormat:Panel DiscussionsLocation:Pennsylvania Biotechnology Center 3805 Old Easton Road, Doylestown, PA 18902  

For more information and a complete agenda, please refer to https://pabiocenter.org/pabc-calendar/.

About Aprea Therapeutics

Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently associated with chemotherapy and other treatments. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, colorectal, prostate, and breast cancers. The company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Investor Contact:

Mike Moyer
LifeSci Advisors
[email protected]

Media Contact:

Sean Naughton Ph.D.
Russo Partners, LLC
[email protected]
(858) 717-2310


Risks

  • Clinical and regulatory risks associated with the development of APR-1051 and ATRN-119 as they are in clinical stages and not yet approved.
  • Market and competitive risk in oncology drug development, with many companies aiming at targeted therapies and biomarker-defined cancers.
  • Dependence on successful investor and partner engagement at upcoming conferences for funding and business development, which can influence future growth.

More from Press Releases

Harmony Biosciences to Participate in Upcoming Investor Conferences Nov 19, 2026 Pure Cycle Announces Record Financial Results For the Year Ended August 31, 2026 Nov 18, 2026 Sachem Capital Reports Third Quarter 2026 Results Nov 16, 2026 Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026